Abstract: Dosage forms of sodium {4-[5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-benzoimidazole-1-sulfonyl]-phenoxy}-acetate, and methods of use of the dosage forms are disclosed herein.

Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.

Abstract: Dosage forms of sodium {4-[5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-benzoimidazole-1-sulfonyl]-phenoxy}-acetate, and methods of use of the dosage forms are disclosed herein.

Abstract: A system obtains ratings associated with a first set of advertisements hosted by one or more servers, where the ratings indicate a quality of the first set of advertisements. The system observes multiple different first user actions associated with user selection of advertisements of the first set of advertisements and derives a statistical model using the observed first user actions and the obtained ratings. The system further observes second user actions associated with user selection of a second advertisement hosted by the one or more servers and uses the statistical model and the second user actions to estimate a quality of the second advertisement.

Abstract: A system provides one or more advertisements to users in response to search queries and logs user behavior associated with user selection of the one or more advertisements. The system also logs features associated with selected ones of the one or more advertisements, or associated with the search queries. The system further uses a statistical model and the logged user behavior to estimate quality scores associated with the selected advertisements and aggregates the estimated quality scores. The system predicts the quality of another advertisement using the aggregated quality scores.

Abstract: A system obtains a first parameter (QP1) associated with a quality of an advertisement among multiple advertisements, where the first quality parameter (QP1) does not include a click through rate (CTR). The system functionally combines the first quality parameter (QP1) with at least one other parameter and uses the functional combination to filter, rank or promote the advertisement among the multiple advertisements.

Abstract: A method and system for producing graphics. A hierarchical structure of a database is determined. A visual table, comprising a plurality of panes, is constructed by providing a specification that is in a language based on the hierarchical structure of the database. In some cases, this language can include fields that are in the database schema. The database is queried to retrieve a set of tuples in accordance with the specification. A subset of the set of tuples is associated with a pane in the plurality of panes.

Abstract: Disclosed are methods of preventing or treating a disease or adverse condition affecting the gastrointestinal tract of a mammal which comprise orally administering to a mammal a therapeutically effective amount of a prodrug of a proton pump inhibitor and an effective amount of a trefoil family factor peptide, mucoadhesive agent, or a combination thereof. Also disclosed are compositions which are suitable for use in a pharmaceutical dosage form. These compositions comprise a prodrug of a proton pump inhibitor, and also comprise a trefoil family factor peptide, a mucoadhesive component, or a combination thereof.

Abstract: Oral dosage forms, methods of treating diseases or adverse conditions, and methods of inhibiting gastric acid secretion related to prodrugs of a proton pump inhibitor are disclosed herein. Certain embodiments relate to the membrane permeability of the proton pump inhibitor and/or the membrane permeability of the prodrug. Other embodiments relate to prodrugs comprising an acidic functional group and a sulfonyl moiety. In other embodiments, the prodrug is a carboxylic acid which comprises a phenylsulfonyl moiety. Other embodiments relate to the pH of dosage forms and dosage forms comprising salts of acidic functional groups.

Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.

Abstract: Methods including systemically, preferably orally, administering retinoid components to a human or animal to provide the desired therapeutic effect and at least one fewer drug interaction or at least one reduced drug interaction.

Abstract: Methods including orally administering retinoid components to a human or animal to provide a substantially equivalent bioavailability of the retinoid component to the human or animal without regard to the body weight of the human or animal.